期刊
NATURE NEUROSCIENCE
卷 19, 期 11, 页码 1392-1396出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nn.4411
关键词
-
资金
- Medical Research Council [MR/N015746/1, G0701748] Funding Source: researchfish
- MRC [MR/N015746/1, G0701748] Funding Source: UKRI
- Medical Research Council [G0701748, MR/N015746/1] Funding Source: Medline
- NIMH NIH HHS [U01 MH109536, U01 MH109528] Funding Source: Medline
Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据